AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype?

Jieni Zhang 1 · Yin Chen 1 · Jiaxin Chen 1 · Xin Huang 1 · Haiyan Wang 1 · Yan Li 1 · Weibin Liu 1 · Huiyu Feng 1

Received: 15 September 2020 / Accepted: 4 January 2021 / Published online: 12 January 2021
© The Author(s) 2021

Abstract
Introduction This study investigated the characteristics of double-seropositive myasthenia gravis (DSP-MG) in southern China for disease subtype classification.

Methods A case-control study was carried out in which the characteristics of DSP-MG patients (n = 17) were compared to those of muscle-specific tyrosine kinase antibody-positive (MuSK)-MG and acetylcholine receptor antibody-positive (AChR)-MG patients (n = 8 and 27, respectively). We also performed a literature review of DSP-MG patients.

Results Compared to AChR-MG, DSP-MG had greater bulbar dysfunction (47.1% vs 18.6%, P = 0.04), higher incidence of myasthenia crisis (41.2% vs 14.8%, P = 0.04), more severe Myasthenia Gravis Foundation of America classification at maximum worsening, greater autoantibody abnormalities (70.6% vs 33.3%, P = 0.015), greater need for immunosuppressant treatment (58.8% vs 3.7%, P < 0.001), and worse prognosis with less remission (11.8% vs 55.6%, P = 0.001). There were no differences between DSP-MG and MuSK-MG patients. DSP-MG described in published reports was comparable to MuSK-MG.

Discussion DSP-MG in southern China may be a subtype of MuSK-MG.

Keywords Myasthenia gravis · Antibody · Acetylcholine receptor · Muscle-specific tyrosine kinase · Double-seropositive myasthenia gravis · Subtype

Introduction
Myasthenia gravis (MG) is an autoimmune disease involving 3 autoantibodies—namely, acetylcholine receptor antibody (AChRAb), muscle-specific tyrosine kinase antibody (MuSKAb), and low-density lipoprotein receptor-associated protein 4 antibody [1]. These are useful for identifying different subsets of MG patients as a prerequisite for accurate diagnosis and effective disease management. Previous studies have reported that in a small proportion of cases, AChRAb and MuSKAb coexist [1, 2]; however, it is unclear whether double-seropositive (DSP)-MG is more similar to AChR-MG or MuSK-MG or is a distinct clinical entity. In order to correctly classify and provide treatment tailored to DSP-MG patients, we compared the characteristics of AChR-MG, MuSK-MG, and DSP-MG cases at our hospital.

Methods
Subjects
This retrospective case-control study was conducted at the First Affiliated Hospital of Sun Yat-sen University between 2015 and 2018. Inclusion criteria were as follows: (1) patients diagnosed with MG based on typical clinical presentation and/or examination; (2) positivity for AChRAb, MuSKAb, or both; and (3) follow-up at least 2 years. Exclusion criteria were as follows: (1) patients with severe heart, lung, or kidney disease or multivisceral failure; (2) incomplete data; and (3) age < 18 years old. The study was approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University.
Methods

Patients were grouped according to antibody specificity as follows. AChRAb-positive patients were assigned to the AChR-MG group; MuSKAb-positive patients were assigned to the MuSK-MG group; and patients positive for both AChRAb and MuSKAb constituted the DSP-MG group. The following information was collected for each patient: sex; age of MG onset; clinical stage at onset; Myasthenia Gravis Foundation of America (MGFA) classification at maximum worsening; bulbar dysfunction; myasthenia crisis; thymus imaging; electrophysiology; thyroid function; autoantibodies, including anti-double-stranded DNA, anticentromere, anti-extractable nuclear antigen (Smith protein, ribonucleoprotein, Robert antigen/Sjögren’s A, and Lane antigen/Sjögren’s B), antiribosome, antinucleosome, antihistone, antimitochondrion, and antinuclear antibodies; response to treatment; and prognosis (based on prognostic immune score [PIS]).

Autoantibody assay

AChRAb, MuSKAb, and other antibodies were detected by enzyme-linked immunosorbent assay (ELISA) with commercial ELISA kits (RSR, Cardiff, UK). The experiment was performed at Guangzhou Da’an Clinical Test Center. Patients were defined as antibody positive for antibody titers of ≥ 0.45 nmol/l (AChRAb) and > 9.5 pmol/l (MuSKAb).

Statistical analysis

Data analysis was performed using SPSS v23.0 (SPSS Inc., Chicago, IL, USA). Quantitative data were assessed with the independent samples t test, and qualitative data were evaluated with the chi-square test, Fisher’s exact test, or rank sum test. For all tests, P ≤ 0.05 was considered statistically significant.

Results

Characteristics of DSP-MG vs AChR-MG

We compared the characteristics of 17 DSP-MG, 8 MuSK-MG, and 27 AChR-MG patients (Table 1). DSP-MG patients had greater bulbar palsy dysfunction, a higher incidence of myasthenia crisis, higher MGFA classification at maximum worsening, more autoantibody abnormalities, greater need for immunosuppressants, and a lower rate of pharmacologic remission. DSP-MG was more prevalent in females and was less frequently of the ocular type compared to AChR-MG, although the differences were nonsignificant.

Characteristics of DSP-MG vs MuSK-MG

There were no significant differences between DSP-MG and MuSK-MG in terms of demographics, clinical features, treatment, and prognosis (Table 2).

Discussion

This study compared the clinical features and treatment response of 3 subtypes of MG at a hospital in southern China. We found that in both respects, DSP-MG was more similar to MuSK-MG than to AChR-MG, leading us to conclude that DSP-MG in southern China is a subtype of MuSK-MG.

Bulbar dysfunction and respiratory weakness are typical features of MuSK-MG [3, 4]. In our study, almost half of DSP-MG patients showed bulbar dysfunction, including dysarthria and dysphagia. Additionally, most of these patients experienced myasthenia crisis, which occurs in MuSK-MG. The comparison between DSP-MG and MuSK-MG patients revealed no significant differences, supporting our conclusion that they are related diseases.

The clinical manifestations of MuSK-MG tend to be worse than those of AChR-MG [3, 4]. The MGFA classification is widely used to evaluate the severity of MG, mainly based on the affected muscle groups. The most common MGFA classification at maximal worsening in AChR-MG patients was MGFA I, which indicated that weakness was mostly restricted to the ocular muscles. In contrast, most DSP-MG patients were classified as MGFA II, and the rate was higher than in AChR-MG patients; moreover, there were more patients with MGFA III to V in the DSP-MG group than in the AChR-MG group. These results indicate that DSP-MG is associated with a more severe disease status than AChR-MG and is thus more comparable to MuSK-MG. This was underscored by the fact that there was no significant difference between DSP-MG and MuSK-MG in terms of MGFA classification.

MG is an autoimmune disease that has been linked to thyroid dysfunction and autoantibody production. MG often co-occurs with other autoimmune diseases such as Graves’ disease and systemic lupus erythematos. AChR-MG is associated with abnormal thyroid function, and about 26.5% of patients have comorbid Graves’ disease [5]. On the other hand, MuSK-MG is more likely to co-occur with autoantibody diseases such as Hashimoto thyroiditis and rheumatoid arthritis (9.6%) [5]. In our study, autoantibody production was more frequently observed in DSP-MG than in AChR-MG, but there was no significant difference between DSP-MG and MuSK-MG, suggesting that they share similar pathogenic mechanisms.
### Table 1 Characteristics of AChR-MG, MuSK-MG, and DSP-MG patients

|                          | AChR-MG (n = 27) | MuSK-MG (n = 8) | DSP-MG (n = 17) | P1 value (AChR-MG vs DSP-MG) | P2 value (MuSK-MG vs DSP-MG) |
|--------------------------|------------------|----------------|-----------------|-----------------------------|-----------------------------|
| Age, years               | 37.24±14.07      | 39.24±14.65    | 40.76±14.33     | 0.539                       | 0.734                       |
| Age of onset, years      | 35.37±18.25      | 38.63±16.91    | 38.41±18.00     | 0.591                       | 0.978                       |
| 0–18, n (%)              | 5 (18.5)         | 1 (12.5)       | 2 (11.8)        | 0.910                       | 0.825                       |
| 19–50, n (%)             | 16 (59.3)        | 4 (50.0)       | 11 (64.7)       |                            |                            |
| >50, n (%)               | 6 (22.2)         | 3 (37.5)       | 4 (23.5)        |                            |                            |
| Sex, n (%)               |                  |                |                 | 0.109                       | 1.000                       |
| Male                     | 11 (40.7)        | 1 (12.5)       | 3 (17.6)        |                            |                            |
| Female                   | 16 (59.3)        | 7 (87.5)       | 14 (82.4)       |                            |                            |
| Clinical stage at onset, n (%) |                |                |                 | 0.276                       | 1.000                       |
| Ocular*                  | 22 (81.5)        | 4 (50.0)       | 10 (58.8)       |                            |                            |
| Generalized**            | 5 (18.5)         | 4 (50.0)       | 7 (41.2)        |                            |                            |
| Bulbar dysfunction, n (%)| 5 (18.6)         | 5 (62.5)       | 8 (47.1)        | 0.040                       | 0.673                       |
| Myasthenia crisis, n (%) | 4 (14.8)         | 3 (37.5)       | 7 (41.2)        | 0.040                       | 0.860                       |
| MGFA classification at maximum worsening, n (%) | 0.034            | 0.322          |                 |                            |                            |
| I                        | 14 (51.9)        | 2 (25.0)       | 4 (23.5)        |                            |                            |
| II                       | 8 (29.6)         | 1 (12.5)       | 6 (35.3)        |                            |                            |
| III                      | 5 (18.5)         | 2 (25.0)       | 5 (29.4)        |                            |                            |
| IV                       | 0 (0.0)          | 1 (12.5)       | 1 (5.9)         |                            |                            |
| V                        | 0 (0.0)          | 2 (25.0)       | 1 (5.9)         |                            |                            |
| Mean duration before the max MGFA occur, months | 14.97            | 11.33          | 14.76           | 0.985                       | 0.552                       |
| Autoantibody abnormality, n (%) | 9 (33.3)        | 3 (37.5)       | 12 (70.6)       | 0.015                       | 0.194                       |

**AChR-MG** acetylcholine receptor antibody-positive myasthenia gravis, **DSP-MG** double-seropositive myasthenia gravis, **MGFA** Myasthenia Gravis Foundation of America, **MuSK-MG** muscle-specific tyrosine kinase antibody-positive myasthenia gravis

* It included those who were with the onset of ocular muscle and maintain as ocular MG during the follow-up period

** It included those who were with the onset of generalized muscle, as well as those with the onset of ocular muscle and then developed into generalized MG during the follow-up period

### Table 2 Treatment and prognosis of AChR-MG, MuSK-MG, and DSP-MG patients

| Treatment         | AChR-MG (n = 27) | MuSK-MG (n = 8) | DSP-MG (n = 17) | P1 value (AChR-MG vs DSP-MG) | P2 value (MuSK-MG vs DSP-MG) |
|-------------------|------------------|----------------|-----------------|-----------------------------|-----------------------------|
| PYR               | 2 (7.4)          | 2 (25.0)       | 0 (0)           | <0.001                      | 0.475                       |
| PYR + PRE         | 24 (88.9)        | 2 (25.0)       | 7 (41.2)        |                            |                            |
| PYR + IMM         | 1 (3.7)          | 4 (50.0)       | 10 (58.8)       |                            |                            |
| IVIG              | 3 (11.1)         | 3 (37.5)       | 3 (17.6)        | 0.538                       | 0.344                       |
| Plasma exchange   | 0 (0.0)          | 0 (0.0)        | 0 (0.0)         | 1.000                       | 1.000                       |
| Prognosis         |                  |                |                 | 0.001                       | 0.628                       |
| CSR               | 2 (7.4)          | 0 (0.0)        | 0 (0.0)         |                            |                            |
| PR                | 15 (55.6)        | 2 (25.0)       | 2 (11.8)        |                            |                            |
| MM                | 10 (37.0)        | 6 (75.0)       | 15 (88.2)       |                            |                            |

**AChR-MG** acetylcholine receptor antibody-positive myasthenia gravis, **CSR** complete stable remission, **DSP-MG** double-seropositive myasthenia gravis, **IMM** immunosuppressant, **IVIG** intravenous immunoglobulin, **MM** minimal manifestations, **MuSK-MG** muscle-specific tyrosine kinase antibody-positive myasthenia gravis, **PR** pharmacologic remission, **PRE** prednisone, **PYR** pyridostigmin
Thymoma occurs in about 10–15% patients in AChR-MG but is rare in MuSK-MG [1]; therefore, thymectomy is not recommended in the latter case as no therapeutic benefit has been demonstrated [3, 4]. The high rate of thymoma among the 17 DSP-MG patients at our hospital was inconsistent with the reported rarity of thymoma in MuSK-MG. A possible reason for this incongruity is that most of our DSP-MG patients (11/17) were also positive for ryanodine receptor and titin antibodies, which occurs at a high frequency in thymoma-associated MG [1]. Thymectomy results in satisfactory improvement in thymoma-associated DSP-MG patients; therefore, although the presentation of DSP-MG is similar to that of MuSK-MG, thymectomy should be considered when thymoma is present.

In terms of treatment response, AChR-MG patients are more sensitive to cholinesterase inhibitors whereas MuSK-MG patients often require additional therapeutic interventions such as prednisone and other immunosuppressants; this difference between the 2 subtypes of MG may be attributable to differences in pathogenic mechanisms and disease severity [1, 3, 4]. MuSK-MG also has worse prognosis than AChR-MG as a result of drug insensitivity and more aggressive disease course [1, 3, 4]. In the present study, we evaluated prognosis using the PIS, which includes complete stable remission, pharmacologic remission, and mild medicine in order of worsening prognosis. None of the DSP-MG patients in our study responded to cholinesterase inhibitors and more required immunosuppressants compared to AChR-MG patients. Moreover, the rate of pharmacologic remission was lower in DSP-MG than in AChR-MG, reflecting the poorer prognosis of the former group. However, there were no differences in treatment response or prognosis between DSP-MG and MuSK-MG.

Thymoma occurs in about 10–15% patients in AChR-MG but is rare in MuSK-MG [1]; therefore, thymectomy is not recommended in the latter case as no therapeutic benefit has been demonstrated [3, 4]. The high rate of thymoma among the 17 DSP-MG patients at our hospital was inconsistent with the reported rarity of thymoma in MuSK-MG. A possible reason for this incongruity is that most of our DSP-MG patients (11/17) were also positive for ryanodine receptor and titin antibodies, which occurs at a high frequency in thymoma-associated MG [1]. Thymectomy results in satisfactory improvement in thymoma-associated DSP-MG patients; therefore, although the presentation of DSP-MG is similar to that of MuSK-MG, thymectomy should be considered when thymoma is present.

In terms of treatment response, AChR-MG patients are more sensitive to cholinesterase inhibitors whereas MuSK-MG patients often require additional therapeutic interventions such as prednisone and other immunosuppressants; this difference between the 2 subtypes of MG may be attributable to differences in pathogenic mechanisms and disease severity [1, 3, 4]. MuSK-MG also has worse prognosis than AChR-MG as a result of drug insensitivity and more aggressive disease course [1, 3, 4]. In the present study, we evaluated prognosis using the PIS, which includes complete stable remission, pharmacologic remission, and mild medicine in order of worsening prognosis. None of the DSP-MG patients in our study responded to cholinesterase inhibitors and more required immunosuppressants compared to AChR-MG patients. Moreover, the rate of pharmacologic remission was lower in DSP-MG than in AChR-MG, reflecting the poorer prognosis of the former group. However, there were no differences in treatment response or prognosis between DSP-MG and MuSK-MG.

Other patient characteristics were similar between DSP-MG and MuSK-MG including the predominance of females and the higher rates of response to repetitive nerve electrical stimulation (RNS) [6] and plasma exchange [3]. Given the small size of our study population, the higher frequency of DSP-MG in women may not be significant, while the lower positive response rates may be due to technical issues and the limited number of samples. As there were no patients in our study who were treated by plasma exchange, it is unclear whether this approach can yield a better outcome.

A systematic review of the literature [7–25] published between 2005 and 2019 revealed 28 cases of DSP-MG (Table 3). Over 70% (20/28) of DSP-MG patients were female, suggesting a trend of female dominance. After removing 10 items with missing data, the initial site of DSP-MG development was in most cases the ocular (16/18) and bulbar (7/18) muscles; after removing 5 items, MGFA IIb was the most common clinical classification (8/23), indicating that bulbar weakness is a feature of DSP-MG patients. All of these features are similar to those of MuSK-MG. For thymus imaging, 4 of the remaining 9 cases had a normal thymus whereas hyperplasia and thymoma were observed in 3 and 2 cases, respectively. Previous studies have shown that MuSK-MG presents with either a normal or atrophied thymus [3–5], while thymus hyperplasia and thymoma are more common in AChR-MG [5]. Therefore, it is difficult to identify the DSP subgroup of MG based on thymus imaging. Electromyography results were mostly abnormal (9/14), which may be related to the high rate of positive response observed in MuSK-MG [6]. In terms of treatment and prognosis [2], pyridostigmin was effective in 2/20 cases, while the remaining 18 cases were treated with a combination of prednisone or immunosuppressants, intravenous immunoglobulin, or plasma exchange.

Nine patients showed clinical improvement; 3 improved after plasma exchange; and 1 responded to rituximab. Taken together, these observations underscore the similarity of DSP-MG to MuSK-MG [3, 4].

| Table 3 | Supplemental data of clinical characteristics |
|---------|----------------------------------------------|
|         | AChR-MG (n = 27) | MuSK-MG (n = 8) | DSP-MG (n = 17) | P1 value (AChR-MG vs DSP-MG) | P2 value (MuSK-MG vs DSP-MG) |
| Thymus type, n (%) |                    |                  |                 |                            |                            |
| Thymoma | 7 (26.0) | 0 (0.0) | 5 (29.4) | 0.355 | 0.230 |
| Hyperplasia | 10 (37.0) | 7 (87.5) | 9 (53.0) |                  |                            |
| Thymic atrophy | 10 (37.0) | 1 (12.5) | 3 (17.6) |                  |                            |
| RNS positive, n (%) | 8 (29.6) | 3 (37.5) | 10 (58.8) | 0.060 | 1.000 |
| Abnormal thyroid function, n (%) | 5 (18.5) | 1 (12.5) | 3 (17.6) | 1.000 | 1.000 |

AChR-MG acetylcholine receptor antibody-positive myasthenia gravis, DSP-MG double-seropositive myasthenia gravis, MuSK-MG muscle-specific tyrosine kinase antibody-positive myasthenia gravis, RNS repetitive nerve electrical stimulation.
Table 4  Characteristics of DSP-MG in the literature

| Number | Reference | Country  | Age of onset (years) | Sex | Region of onset | MGFA | EMG | Treatment          | Prognosis                                 |
|--------|-----------|----------|----------------------|-----|-----------------|------|-----|------------------|-------------------------------------------|
| 1      | 7         | Spain    | 45                   | F   | Ocular, bulbar  | IIb  | Nor | PRE, IVIG        | Worse, improved with rituximab            |
| 2      | 8         | China    | 42                   | M   | Ocular          | I    | Abn | PRE              | Improved                                  |
| 3      | 9         | Greece   | 71                   | F   | Ocular          | I    | Abn | PYR, PRE         | Improved                                  |
| 4      | 9         | Greece   | 52                   | M   | NA              | NA   | NA  | NA               | NA                                        |
| 5      | 9         | Greece   | 43                   | M   | NA              | NA   | NA  | NA               | NA                                        |
| 6      | 9         | Greece   | NA                   | F   | NA              | NA   | NA  | NA               | NA                                        |
| 7      | 9         | Greece   | NA                   | F   | NA              | NA   | NA  | NA               | NA                                        |
| 8      | 9         | Greece   | 19                   | F   | Ocular          | IIb  | NA  | PYR, PRE, PLEX   | Worse, improved with PLEX                 |
| 9      | 12        | Sweden   | 61                   | M   | Ocular          | I    | Abn | NA               | NA                                        |
| 10     | 12        | Sweden   | 24                   | F   | NA              | I Va | NA  | NA               | NA                                        |
| 11     | 12        | Sweden   | 45                   | F   | NA              | Ila  | Abn | PRE, PRE         | NA                                        |
| 12     | 12        | Sweden   | 36                   | F   | NA              | Ila  | NA  | PRE, PLEX        | NA                                        |
| 13     | 12        | Sweden   | 42                   | F   | NA              | Ila  | NA  | PRE, PRE         | NA                                        |
| 14     | 13        | Germany  | 62                   | M   | Ocular, bulbar  | IIb  | Abn | PYR, PRE, IVIG, PLEX | Worse, improved with PLEX              |
| 15     | 14        | Poland   | 13                   | F   | Ocular, limb    | IIIa | Abn | PRE, IMM         | Worse                                     |
| 16     | 15        | UK       | 13                   | F   | Ocular, bulbar  | IVb  | NA  | PRE, PLEX        | Worse                                     |
| 17     | 16        | Greece   | 35                   | F   | Ocular, bulbar  | IIb  | Abn | PYR, PRE         | Improved                                  |
| 18     | 17        | India    | 23                   | F   | Ocular, bulbar  | IIb  | Abn | PYR              | Improved                                  |
| 19     | 18        | USA      | 2                    | F   | Ocular          | IIa  | Abn | PYR, PRE, IVIG   | Worse                                     |
| 20     | 19        | China    | 75                   | M   | Bulbar, limb    | IIb  | Nor | PYR, PRE, IVIG   | Worse                                     |
| 21     | 20        | China    | 51                   | F   | Ocular          | I    | NA  | PYR, PRE, IVIG   | Improved                                  |
| 22     | 21        | USA      | 41                   | F   | Ocular          | IIb  | NA  | PYR, PRE, IVIG   | Improved                                  |
| 23     | 22        | USA      | 2                    | F   | Bulbar, limb    | NA   | NA  | PYR, PRE, IMM    | Improved                                  |
| 24     | 23        | USA      | 10                   | F   | Ocular          | I Va | Nor | PYR, PLEX        | Worse                                     |
| 25     | 24        | China    | NA                   | M   | NA              | Ila  | NA  | NA               | NA                                        |
| 26     | 24        | China    | NA                   | F   | NA              | IVb  | NA  | NA               | NA                                        |
| 27     | 25        | China    | 59                   | M   | Ocular          | IIb  | Nor | PYR, PRE         | Improved                                  |
| 28     | 25        | China    | 49                   | F   | Ocular          | IIb  | Nor | PYR, PRE         | Improved                                  |

Abn abnormal, EMG electromyography, F female, IMM immunosuppressant, IVIG intravenous immunoglobulin, M male, NA not available, Nor normal, PLEX plasma exchange, PRE prednisone, PYR pyridostigmin.
In conclusion, although our study was limited by a small sample size, the results of our analyses and the literature search suggest that DSP-MG is a subtype of MuSK-MG. These findings can facilitate the diagnosis and treatment of DSP-MG in order to achieve better clinical outcomes (Table 4).

Acknowledgments This work was supported by the Project of Guangzhou Science Technology and Innovation Commission (no. 201707010122); Guangdong Natural Science Foundation Committee (nos. 2017A030313829 and 2018A030313449); National Key R&D Program of China (no. 2017YFC0907700); and grants from the Southern China International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases (no. 2015B050501003), Guangdong Provincial Engineering Center For Major Neurological Disease Treatment, Guangdong Provincial Translational Medicine Innovation Platform for Diagnosis and Treatment of Major Neurological Disease, and Guangdong Provincial Clinical Research Center for Neurological Diseases.

Authors’ contributions Jieni Zhang, MD, designed and conceptualized the study, analyzed the data, and drafted the manuscript for intellectual content. Yin Chen designed and conceptualized the study, analyzed the data, and drafted the manuscript for intellectual content. Jiaxin Chen, MD, had a major role in the acquisition of data. Xin Huang, MD, PhD, had major role in the acquisition of data. Yan Li, MD, PhD, had a major role in the acquisition of data. Haiyan Wang, MD, had a major role in the acquisition of data. Weibin Liu, MD, PhD, interpreted the data and revised the manuscript for intellectual content. Huiyu Feng, MD, PhD, interpreted the data and revised the manuscript for intellectual content.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval Institutional review board approval of our hospital was obtained for this study.

Informed consent All patients involved in this study gave their informed consent.

Ethical publication statement We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Abbreviations AChR, acetylcholine receptor; AChRAb, acetylcholine receptor antibody; AChR-MG, acetylcholine receptor antibody-positive myasthenia gravis; CSR, complete stable remission; DSP-MG, double-seropositive myasthenia gravis; IMM, immunosuppressant; IVIG, intravenous immunoglobulin; MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America; MuSK, muscle-specific tyrosine kinase; MuSKAb, muscle-specific tyrosine kinase antibody; MuSK-MG, muscle-specific tyrosine kinase antibody-positive myasthenia gravis; MM, minimal manifestations; PIS, prognostic immune score; PR, pharmacologic remission; PRE, prednisone; PYR, pyridostigmine; PLEX, plasma exchange; RNS, repetitive nerve electrical stimulation

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Gilhus NE, Verschueren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023–1036
2. Tsonis AI, Zisimopoulou P, Lazaridis K, Tzartos J, Matsigkou E (2015) Zouvelou, et al. MuSK autoantibodies in myasthenia gravis detected by cell based assay—a multinational study. J Neuroimmunol 284:10–17
3. Muppidi S, Wolfe GI (2009) Muscle-specific receptor tyrosine kinase antibody-positive and seronegative myasthenia gravis. Front Neurol Neurosci 26:109–119
4. Cuptill JT, Sanders DB (2010) Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 23:530–535
5. Nakata R, Motomura M, Masuda T, Shiraiishi H, Tokuda M, Fukuda T et al (2013) Thymus histopathology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis [J]. Eur J Neurol 20:1272–1276
6. Shin JO, Morgan MB, Lu L, Hatanaka Y, Hemmi S et al (2012) Different characteristic phenotypes according to antibody in myasthenia Gravis [J]. J Clin Neuromuscul Dis 14(2):57–65
7. Diaz-Manera J, Rojas-Garcia R, Gallardo E, Juarez C, Martinez-Domeno A, Martinez-Ramirez S et al (2007) Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan’s syndrome. Nat Clin Pract Neurol 3:405–410
8. Yuan L, Lan C, Yi-fan Z (2015) The detection and clinical characteristics of serum positive of MuSK-Ab and double-seronegative in patients with MG. J Apoplex Nervous Dis 04:354–356
9. Poulos K, Koutsouraki E, Kordas G, Kokla A, Tzartos SJ (2012) Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J Neuroimmunol 250:94–98
10. Zouvelou V, Zisimopoulou P, Psmenou E, Matsigkou E, Stamboulos E, Tzartos SJ (2014) AChR-myasthenia gravis switching to double-seropositive several years after the onset. J Neuroimmunol 267:111–112
11. Zouvelou V (2018) Double Seropositive Myasthenia Gravis: A 5-Year Follow-Up. Muscle Nerve 57:E129
12. Rostedt Punga A, Ahlgqvist K, Bartoccioni E, Scuderi F, Marino MB, Suomalainen A et al (2006) Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol 117:1434–1443
13. Jordan B, Schilling S, Zierer S (2016) Switch to double positive late onset MuSK myasthenia gravis following thymectomy in paraneoplastic AChR antibody positive myasthenia gravis. J Neurol 263:174–176
14. Kostera-Pruszczyk A, Kwiecinski H (2009) Juvenile seropositive myasthenia gravis with anti-MuSK antibody after thymectomy. J Neurol 256:1780–1781
15. Rajakulendran S, Viegas S, Spillane J, Howard RS (2012) Clinically biphasic myasthenia gravis with both AChR and MuSK antibodies. J Neurol 259:2736–2739

16. Zouvelou V, Kyriazi S, Rentzos M, Belimezi M, Micheli MA, Tzartos SJ et al (2013) Double-seropositive myasthenia gravis. Muscle Nerve 47:465–466

17. Suhail H, Vivekanandhan S, Singh S, Behari M (2010) Coexistent of muscle specific tyrosine kinase and acetylcholine receptor antibodies in a myasthenia gravis patient. Neurol India 58:668–669

18. Saulat B, Maertens P, Hamilton WJ, Bassam BA (2007) Anti-musk antibody after thymectomy in a previously seropositive myasthenic child. Neurology 69:803–804

19. Wei C (2015) One cases of antibody of AChR and MuSK double seropositive myasthenia gravis. Journal of Clinical Neurology in Chinese 28:258–261

20. Ju L, Zhiyun L, Hongxi C, Ziyin S, Huiru F, Xiaohui M, et al. West China Medical Journal in Chinese 2018; 33:696–702

21. Al Saleh A, Cariga P (2007) Myasthenia gravis with AChR and MuSK antibodies positivity: case report. Clinical Neurophysiology 118(5):e165

22. Skjei KL, Lennon VA, Kuntz NL (2013) Muscle specific kinase autoimmune myasthenia gravis in children: a case series. Neuromuscul Disord 23(11):874–882

23. Sanders DB, Juel VC (2008) MuSK-antibody positive myasthenia gravis: questions from the clinic. J Neuroimmunol 201–202:85–89

24. Xin-xin F (2013) Detection and significance of anti-AchR antibodies and anti-MuSK antibodies in serum of myasthenia gravis. J. Med. Sci. Yanbian Univ 03:167–169

25. Mingqiang L, Lu R, Yingna Z, Jie L, Hua F, Jing Z et al (2008) Clinical characteristics of AChRAb and MuSKAb double seropositive myasthenia gravis patients. Clinical Neurology and Neurosurgery 172:69–73

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.